We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » DEVICE FIRM QUESTIONS FDA INSPECTION PROCESS

DEVICE FIRM QUESTIONS FDA INSPECTION PROCESS

June 16, 2006

The FDA issued a May 30 warning letter to Restorative Health Services of Nashville, Tenn., for current good manufacturing practices (cGMP) violations related to the firm's cranial orthosis device -- a "helmet" designed to prevent the continued development of an abnormally-shaped head. The firm also failed to follow medical device reporting regulations, the FDA said.

But Restorative Health's CEO has serious questions about the justification for that letter and the FDA's inspection process of his company's facility.

An FDA investigator inspected the company's facility Jan. 23, 30 and 31 and issued the company a Form 483 branding the firm's cranial orthosis product "adulterated."

Specifically, the company's April 3 response letter to the agency "does not contain a [ corrective and preventive action] CAPA procedure," the warning letter says. Furthermore, "your firm does not have any acceptance activity procedures for the components received from your suppliers," the agency says.

In addition, the QS procedure submitted in the firm's April 3 response "does not include procedures for identification, documentation, validation, or, where appropriate, verification, review, and approval of design changes before their implementation," the warning letter states.

The firm's cranial orthosis is "misbranded" because Restorative Health "failed or refused to furnish material or information" and "does not have an internal formal system for evaluating adverse events and submitting" the required medical device reports (MDRs) to the FDA, the letter states.

"Here is why we are 'not compliant,'" Aaron Sorensen, Restorative Health's president and CEO, told FDAnews. "When we had our first site visit several years ago, the site inspector told us -- which we also have in writing from the FDA -- that we were exempt from the QS side of the regulation, but we were not exempt from the labeling side." The company was found to be compliant at that time, Sorensen said.

Devices & Diagnostics Letter

(http://www.fdanews.com/ddl/33_24/)

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing